Buy Like Buffett
Watchlist

RHYTHM PHARMACEUTICALS, INC.

RYTM · Healthcare · $6.9B mkt cap · FY2025 filings · · not refreshed in 35 days · Shallow moat ·

Doesn't clear the bar

Shallow moat
Share / Embed this score
Embed this score

The five investor questions

60

2021–2025 (latest 5 aligned FYs; v3 window cap 5): revenue $3.2M to $190M, increasing; diluted EPS -1.40 to -3.11, decreasing.

98

Median gross margin 89.7% over 5y, very stable.

0

Median ROIC -67.5%, above the 12% hurdle in 0% of years.

28

Net debt/EBITDA n/ax, interest coverage -9x.

44

Owner earnings changed trend unclear over up to the ten most recent annual observations, share count n/a.

Price vs. value if growth stopped today

A cautious baseline, not a price target: what the shares may support if normalized owner earnings simply hold steady.

Above value if growth stopped todayBelow value if growth stopped today
No price data
Not reported
Unavailable — insufficient owner-earnings data
Unavailable — insufficient growth-model data
$102.10
No price data

This zero-growth estimate assumes trailing owner earnings persist — unreliable for declining businesses. The recent FY revenue series does not trigger the three-consecutive-declines flag.

Among the current top-score group, the median current price is 239% above the zero-growth estimate across 48 of the current top 50 companies by Moat Score with both values.

Score records captured Jul 26, 2026.

Exactly which 50 companies?

FTNT, META, MEDP, IBEX, MSFT, GOOGL, LULU, ANF, IDXX, TXRH, FHI, QLYS, FFIV, ADBE, LLY, MANH, VEEV, GRMN, SSD, MNST, DOCS, MCO, CPRT, NTAP, LRCX, NVDA, CORT, SFM, MPTI, ULTA, SN, RMD, ROL, PAYC, IRMD, INTU, DECK, MORN, LGCY, DAL, GWW, ISRG, MPWR, CTAS, LOPE, MRK, CMG, FAST, BKNG, ORLY

Missing a usable price or zero-growth estimate: ANF, BKNG.

Model details under moat-index@3.0.0: zero-growth multiple 11.1×, capped-growth comparison at no more than 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.

12 years of fundamentals

The business, in plain English

RHYTHM PHARMACEUTICALS, INC. booked $190M of revenue in FY2025 in the Healthcare sector and kept 89.7% of it as gross profit — a high-margin business by that measure. After every other cost, −103.6% of each revenue dollar reached the bottom line.

It earned −78.6% on invested capital in the latest filed year, FY2025. Across the full 9-year measurable filed record, median ROIC was −67.5%. Over the v3 recent window (9 measurable filed years), median ROIC was −67.5%. The Returns on Capital filter above scores it 0/100.

The balance sheet carried $108M of total debt in FY2025. Balance-Sheet Safety scores it 28/100.

Put together: Pricing Power is the strongest of the five filters (98/100) and Returns on Capital the weakest (0/100), which is how RYTM lands at 46/100 — a Shallow moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

FY2014–FY2025 · 12 fiscal years, normalized from RYTM’s SEC filings

Sales, as filed$190M FY2025
$0$100M$200M2014201820222025
Revenue kept after cost of goods89.7% FY2025
0%50%2014201820222025
Standard ROIC or separately labeled Operating ROICROIC −78.6% FY2025
−400%−200%0%2014201820222025
Cash an owner could take out−$197M FY2025
−$200M−$100M$02014201820222025

Gaps in a line mean that item isn’t in RYTM’s filings for that year. The series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Flagship explainer

How RHYTHM PHARMACEUTICALS, INC. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$190M · 100%Cost of revenue$19.5M · 10%Gross profit$170M · 90%Operating income−$192M · −101%Income before tax−$196M · −103%Income tax$497000 · 0%Net income−$197M · −104%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$190M100%
Cost of revenue$19.5M10%
$170M90%
−$192M−101%
Income before tax−$196M−103%
Income tax$4970000%
−$197M−104%
Source: · event Dec 31, 2025 · retrieved Jul 26, 2026 · annual-row source set
Embed this chart

Flagship explainer

What RHYTHM PHARMACEUTICALS, INC. owns — and owes

RHYTHM PHARMACEUTICALS, INC.'s filing tags don't support a full breakdown — here's what is filed:

Table alternative
Filed lineValue% of assetsSource
Total assets$480M100%
Cash and equivalents$54.3M11%
$108M23%
Stockholders’ equity$139M29%
Source: · event Dec 31, 2025 · retrieved Jul 26, 2026 · annual-row source set

Flagship explainer

What drives RHYTHM PHARMACEUTICALS, INC.’s return on equity?

ROE is five filed business factors multiplied together.

DuPont return on equity factor treeReturn on equity branches into tax burden, interest burden, operating margin, asset turnover, and the equity multiplier.Return on equity−244%Tax burden100%net income ÷ pretax incomeInterest burden102%pretax ÷ operating incomeOperating margin−101%operating income ÷ revenueAsset turnover0.43×revenue ÷ average assetsEquity multiplier5.43×average assets ÷ average equityAs of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com
DuPont source inputs
InputValueFiscal yearSource
−$197MFY2025
Income before tax−$196MFY2025
Operating income−$192MFY2025
$190MFY2025
Ending assets$480MFY2025
Beginning assets$392MFY2024
$139MFY2025
$21.7MFY2024
Source:
  • SEC filingFiling detailsAccession 0001628280-26-012399
· event Dec 31, 2025 · retrieved Jul 26, 2026 · annual-row source set
Embed this chart

Flagship explainer

Where RHYTHM PHARMACEUTICALS, INC.'s cash went

RHYTHM PHARMACEUTICALS, INC.’s filing does not supply enough provenance-matched cash-flow lines for a truthful flow chart — here’s what is filed:

Table alternative
Filed lineValue% of cash from operationsSource
Cash from operations−$116M−100%
Depreciation and amortization$5000000%
Source: · event Dec 31, 2025 · retrieved Jul 26, 2026 · annual-row source set

Curated 19-manager tier

Who reported holding RHYTHM PHARMACEUTICALS, INC.

Delayed public 13F reports for 2026-Q2—not live positions, trades, or recommendations.

0 holding0 exited0 not holding0/19 resolved19 not retrieved

Named manager positions and quarter-over-quarter changes
ManagerReported positionQuarter-over-quarterFiling accession
Abrams CapitalNot retrievedComparison not retrievedFiling not retrieved
Akre CapitalNot retrievedComparison not retrievedFiling not retrieved
Baupost GroupNot retrievedComparison not retrievedFiling not retrieved
Berkshire HathawayNot retrievedComparison not retrievedFiling not retrieved
Brave Warrior AdvisorsNot retrievedComparison not retrievedFiling not retrieved
Dodge & CoxNot retrievedComparison not retrievedFiling not retrieved
First EagleNot retrievedComparison not retrievedFiling not retrieved
FundsmithNot retrievedComparison not retrievedFiling not retrieved
Gardner Russo & QuinnNot retrievedComparison not retrievedFiling not retrieved
Gates Foundation TrustNot retrievedComparison not retrievedFiling not retrieved
Mairs & PowerNot retrievedComparison not retrievedFiling not retrieved
Markel / Markel-GaynerNot retrievedComparison not retrievedFiling not retrieved
Oakmark / Harris AssociatesNot retrievedComparison not retrievedFiling not retrieved
Pershing SquareNot retrievedComparison not retrievedFiling not retrieved
Polen CapitalNot retrievedComparison not retrievedFiling not retrieved
Sequoia / Ruane CunniffNot retrievedComparison not retrievedFiling not retrieved
Southeastern Asset ManagementNot retrievedComparison not retrievedFiling not retrieved
Tweedy, BrowneNot retrievedComparison not retrievedFiling not retrieved
Yacktman Asset ManagementNot retrievedComparison not retrievedFiling not retrieved

Position size uses shares and filed value from each manager’s 13F. Portfolio weight uses the eligible long-share filing denominator. Changes compare only with the immediately preceding calendar quarter.

Source: Filing source not retrieved · event Jun 30, 2026 · retrieved Jul 26, 2026

Flagship explainer

What RHYTHM PHARMACEUTICALS, INC. insiders reported

Records still being gathered — partial as of retrieval Aug 30, 2026.

Partial coverage: the incomplete Form 4 walk cannot establish no activity, an activity date, or zero counts.

Moat Score history

16 logged readings since Jul 17, 2026 · append-only, never rewritten

Moat Score over timeLast scored reading of each day, on the 0–100 scale46.0 / 100
0406080100WideNarrowShallowNo moatJul 17, 2026Jul 26, 2026

Breaks in the line mark methodology or normalizer upgrades — readings across versions aren’t compared, so a level shift there isn’t a change in the business.

Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars

  1. Normalizer upgraded unstamped (version unknown)moat-xbrl-normalizer@1.1.0 — readings across versions aren’t comparedJul 26, 2026
  2. Methodology upgraded moat-index@2.0.0moat-index@3.0.0 — readings across versions aren’t comparedJul 23, 2026
  3. Methodology upgraded moat-index@1.2.0moat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026

Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.

Insider activity

Form 4 reports mix P/S market or private transactions with compensation-plan mechanics. Activity casually described as “insider selling” can include compensation mechanics; awards, tax withholding, and option exercises are shown by their exact filed class here, never collapsed into “Bought” or “Sold.”

These are disclosed filing facts and arithmetic aggregates, not a signal or verdict.

This machine-readable surface covers SEC ownership filings from 2003; it does not represent earlier paper-era records.

Records still being gathered — partial as of retrieval Aug 30, 2026.

Trailing-12-month totals and the 90-day cluster result are withheld because this issuer walk is incomplete.

InsiderShares owned afterDateFiling detail
Joshi ManherChief Medical OfficerGrant, award, or other acquisition (A)Table II · Acquired · Stock Options (Right to Buy)50,000—Grant, award, or other acquisition (A)—50,000Aug 17, 2026
1 filed lot
  • Table II · Stock Options (Right to Buy): 50,000 shares at — (Grant, award, or other acquisition (A)) · code A · owned after 50,000 ·
Joshi ManherChief Medical OfficerGrant, award, or other acquisition (A)Table II · Acquired · Restricted Stock Units25,000—Grant, award, or other acquisition (A)—25,000Aug 17, 2026
1 filed lot
  • Table II · Restricted Stock Units: 25,000 shares at — (Grant, award, or other acquisition (A)) · code A · owned after 25,000 ·
Shulman JosephChief Technical OfficerExercise or conversion of derivative security (M)Table I · Acquired · Common Stock · 1 paired event2,024$6.80$13,76320,994Aug 13, 2026
1 filed lot
  • Table I · Common Stock: 2,024 shares at $6.80 · code M · owned after 20,994 · Paired event: 2,024 Stock Options (Right to Buy) → 2,024 Common Stock ·
Shulman JosephChief Technical OfficerOpen-market or private sale (S)Table I · Disposed · Common Stock5,079$119.75$608,21015,915Aug 13, 2026
1 filed lot
  • Table I · Common Stock: 5,079 shares at $119.75 · code S · owned after 15,915 ·
Shulman JosephChief Technical OfficerExercise or conversion of derivative security (M)Table II · Disposed · Stock Options (Right to Buy) · 1 paired event2,024—Exercise or conversion of derivative security (M)—5,945Aug 13, 2026
1 filed lot
  • Table II · Stock Options (Right to Buy): 2,024 shares at — (Exercise or conversion of derivative security (M)) · code M · owned after 5,945 · Paired event: 2,024 Stock Options (Right to Buy) → 2,024 Common Stock ·
Garfield AlastairChief Scientific OfficerOpen-market or private sale (S)Table I · Disposed · Common Stock7,763$117.5709$912,703See lot detailAug 13, 2026
4 filed lots
  • Table I · Common Stock: 2,007 shares at $116.1093 · code S · owned after 8,051 ·
  • Table I · Common Stock: 1,556 shares at $117.0759 · code S · owned after 6,495 ·
  • Table I · Common Stock: 3,400 shares at $118.2843 · code S · owned after 3,095 ·
  • Table I · Common Stock: 800 shares at $119.1688 · code S · owned after 2,295 ·
Lee Jennifer KaydenEVP, Head of North AmericaExercise or conversion of derivative security (M)Table I · Acquired · Common Stock · 2 paired events56,601$17.6152$997,037See lot detailAug 13, 2026
2 filed lots
  • Table I · Common Stock: 35,000 shares at $24.29 · code M · owned after 54,233 · Paired event: 35,000 Stock Options (Right to Buy) → 35,000 Common Stock ·
  • Table I · Common Stock: 21,601 shares at $6.80 · code M · owned after 75,834 · Paired event: 21,601 Stock Options (Right to Buy) → 21,601 Common Stock ·
Lee Jennifer KaydenEVP, Head of North AmericaOpen-market or private sale (S)Table I · Disposed · Common Stock75,834$117.3818$8,901,5310Aug 13, 2026
1 filed lot
  • Table I · Common Stock: 75,834 shares at $117.3818 · code S · owned after 0 ·
Lee Jennifer KaydenEVP, Head of North AmericaExercise or conversion of derivative security (M)Table II · Disposed · Stock Options (Right to Buy) · 2 paired events56,601—Exercise or conversion of derivative security (M)—See lot detailAug 13, 2026
2 filed lots
  • Table II · Stock Options (Right to Buy): 35,000 shares at — (Exercise or conversion of derivative security (M)) · code M · owned after 36,283 · Paired event: 35,000 Stock Options (Right to Buy) → 35,000 Common Stock ·
  • Table II · Stock Options (Right to Buy): 21,601 shares at — (Exercise or conversion of derivative security (M)) · code M · owned after 0 · Paired event: 21,601 Stock Options (Right to Buy) → 21,601 Common Stock ·
Mazabraud YannEVP, Head of InternationalExercise or conversion of derivative security (M)Table I · Acquired · Common Stock · 1 paired event46,625$6.80$317,050112,655Aug 12, 2026
1 filed lot
  • Table I · Common Stock: 46,625 shares at $6.80 · code M · owned after 112,655 · Paired event: 46,625 Stock Options (Right to Buy) → 46,625 Common Stock ·
Mazabraud YannEVP, Head of InternationalOpen-market or private sale (S)Table I · Disposed · Common Stock57,000$116.1504$6,620,575See lot detailAug 12, 2026
6 filed lots
  • Table I · Common Stock: 2,300 shares at $111.7992 · code S · owned after 110,355 ·
  • Table I · Common Stock: 1,000 shares at $112.856 · code S · owned after 109,355 ·
  • Table I · Common Stock: 3,605 shares at $114.6955 · code S · owned after 105,750 ·
  • Table I · Common Stock: 14,568 shares at $115.427 · code S · owned after 91,182 ·
  • Table I · Common Stock: 18,208 shares at $116.4941 · code S · owned after 72,974 ·
  • Table I · Common Stock: 17,319 shares at $117.4686 · code S · owned after 55,655 ·
Mazabraud YannEVP, Head of InternationalExercise or conversion of derivative security (M)Table II · Disposed · Stock Options (Right to Buy) · 1 paired event46,625—Exercise or conversion of derivative security (M)—35,875Aug 12, 2026
1 filed lot
  • Table II · Stock Options (Right to Buy): 46,625 shares at — (Exercise or conversion of derivative security (M)) · code M · owned after 35,875 · Paired event: 46,625 Stock Options (Right to Buy) → 46,625 Common Stock ·

Source-event as of . Retrieved .

Track record

How RHYTHM PHARMACEUTICALS, INC.’s moat rated in each of the years we can reconstruct from its filings — scored only on what was knowable at the time — and what its price and returns did afterward. The score never saw a price; the two are joined only in hindsight, for education, not as a signal.

Point-in-time scores 2017–2025, one methodology version · reconstructed from filings on file each Dec 31 — never with hindsight

Point-in-time Moat Score (dot colored by tier)Indexed price (total-return (dividends reinvested))Rated Wide-moat that year

How to read this: each dot is what the engine would have scored RYTM on that December 31; the line below is its total-return price path (dividends reinvested) in the years since.

0406080100WideNarrowShallowNo moatPoint-in-time Moat Score50100200Indexed price · log scale (2018 = 100)201720192021202320252026

Two tracks, one timeline: the score has its own 0–100 scale (top), the price its own 100-based scale (bottom) — never a shared axis. The price path is a total-return (dividends reinvested) index built from the same data the forward returns use; gaps in the score line are years with no reconstructed rating (see the table for why). The Table view carries every value.

What followed, in the years it rated Wide

In the reconstructed history shown, RYTM did not rate Wide-moat in any year, so there is no wide-moat track record to report. That absence is itself the honest answer — we don’t manufacture a comparison where the rating never earned one.

Healthcare context

#242 of 710 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

  1. #240LUCY Innovative Eyewear, Inc.46.2Shallow moat
  2. #241ETST EARTH SCIENCE TECH, INC.46.1Shallow moat
  3. #243PAHC Phibro Animal Health Corporation45.9Shallow moat
  4. #244COHR COHERENT CORP.45.8Shallow moat

Compare RYTM with its nearest peers →All Healthcare companies on the Index →

Common questions about RYTM

Does RHYTHM PHARMACEUTICALS, INC. have an economic moat?
Based on its FY2025 SEC filings, the Moat Index scores RHYTHM PHARMACEUTICALS, INC. (RYTM) 46.0 out of 100 — a Shallow moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 60, pricing power 98, returns on capital 0, balance-sheet safety 28, capital allocation 44.
How has RYTM's Moat Score changed over time?
The record logs 16 readings since Jul 17, 2026; the latest reads 46.0 out of 100 (shallow moat). No tier changes on record yet. (Methodology or normalizer upgrades on Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell RYTM. See the disclaimer.